Key result
ViV-TAVI treats severe bioprosthetic aortic stenosis and prompts spontaneous closure of a MAIVF pseudoaneurysm.
Case Report (n=1)
No
ViV-TAVI may offer a less invasive therapeutic option that not only treats bioprosthetic valve degeneration but also resolves associated structural complications like MAIVF pseudoaneurysms.
Answers are grounded in this paper and cite their sources.
May support ViV-TAVI in select redo cases with MAIVF pseudoaneurysm; hypothesis-generating and requires prospective validation.
Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is a minimally invasive and effective alternative to redo surgery in high-risk patients with degenerated surgical bioprosthetic valves. We report a 67-year-old woman with a history of Bentall and redo Bentall procedures who presented with degeneration of a surgical bioprosthesis complicated by a mitral-aortic intervalvular fibrosa (MAIVF) pseudoaneurysm. ViV-TAVI resulted in marked symptomatic improvement and optimal hemodynamic valve performance and was unexpectedly associated with spontaneous closure of the MAIVF pseudoaneurysm.
No takes yet. Share an insight, caveat, or question.
Balaban et al. (2026) conducted a case report in Degenerated surgical bioprosthesis and mitral-aortic intervalvular fibrosa pseudoaneurysm (n=1). Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) was evaluated on Symptomatic improvement, hemodynamic valve performance, and closure of pseudoaneurysm. Valve-in-valve transcatheter aortic valve implantation successfully treated severe bioprosthetic aortic stenosis and resulted in the spontaneous closure of a mitral-aortic intervalvular fibrosa pseudoaneurysm.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: